SK Bioscience Receives Approval for Quadrivalent Influenza Vaccine Administration in Infants and Young Children
[Asia Economy Reporter Cho Hyun-ui] SK Bioscience announced on the 23rd that it has received approval from the Ministry of Food and Drug Safety for the indication of administering its self-developed quadrivalent cell-cultured influenza vaccine, Skycellflu4ga, to infants aged 6 months to under 3 years. With this, Skycellflu4ga can now be administered to all age groups aged 6 months and older.
The company expects that the domestic market expansion and overseas advancement of Skycellflu4ga will gain more momentum. This follows the vaccine's acquisition of WHO PQ (Prequalification) certification last December, the first for a quadrivalent cell-cultured influenza vaccine. Additionally, since flu symptoms are similar to those of COVID-19, market expansion is anticipated this fall.
Hot Picks Today
"Samsung and Hynix Were Once for the Underachievers"... Hyundai Motor Employee's Lament
- "Sold Everything Fearing Bankruptcy, Then It Soared 3,900 Times: How a Stock Once Feared for Delisting Became an AI Powerhouse"
- Court Partially Grants Samsung Electronics' Injunction to Prohibit Industrial Action... 100 Million Won Penalty Per Day for Violations
- [US-China Summit] China to Purchase $17 Billion in US Agricultural Products Annually...Real Gains for Beijing
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
Ahn Jae-yong, CEO of SK Bioscience, stated, “With the approval for infants, the advanced technology cell-cultured influenza vaccine can be administered to all age groups,” adding, “We expect to play a leading role in the influenza vaccine market this year.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
